These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8336506)

  • 1. Modulation of vasopressin actions on human platelets by plasma adenosine and theophylline: gender differences.
    Agarwal KC
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):1012-8. PubMed ID: 8336506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-activating factor (PAF)-induced platelet aggregation. Modulation by plasma adenosine and methylxanthines.
    Agarwal KC; Clarke E; Rounds S; Parks RE; Huzoor-Akbar
    Biochem Pharmacol; 1994 Nov; 48(10):1909-16. PubMed ID: 7986202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of human platelet vasopressin receptor and the relation between vasopressin-induced platelet aggregation and vasopressin binding to platelets.
    Inaba K; Umeda Y; Yamane Y; Urakami M; Inada M
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):377-86. PubMed ID: 2978018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of the aggregation response of human platelets to arginine vasopressin.
    Lachant NA; Smith MR; Xie ZJ; Romani WR
    Am J Hematol; 1995 May; 49(1):56-66. PubMed ID: 7741139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of vasopressin-induced platelet aggregation.
    Filep J; Rosenkranz B
    Thromb Res; 1987 Jan; 45(1):7-15. PubMed ID: 3105115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets.
    Yang X; Disa J; Rao AK
    Thromb Res; 1990 Sep; 59(5):809-18. PubMed ID: 2237837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin acts on platelets to generate procoagulant activity.
    Tomasiak M; Stelmach H; Rusak T; Ciborowski M; Radziwon P
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):615-24. PubMed ID: 18832900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
    Agarwal KC; Buckley RS; Parks RE
    Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
    Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
    Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggregation of human blood platelets by vasopressin.
    Haslam RJ; Rosson GM
    Am J Physiol; 1972 Oct; 223(4):958-67. PubMed ID: 4342380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of human platelet vasopressin receptors.
    Thibonnier M; Roberts JM
    J Clin Invest; 1985 Nov; 76(5):1857-64. PubMed ID: 2997293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet vasopressin receptors in patients with congenital nephrogenic diabetes insipidus.
    Bichet DG; Arthus MF; Lonergan M
    Kidney Int; 1991 Apr; 39(4):693-9. PubMed ID: 1828844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of V1a vasopressin receptor gene single nucleotide polymorphisms in platelet vasopressin responsiveness.
    Hasan KN; Shoji M; Tsutaya S; Kudo R; Matsuda E; Saito J; Kimura T; Yasujima M
    J Clin Lab Anal; 2006; 20(3):87-92. PubMed ID: 16721832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of arginine vasopressin (AVP) infusions on circulating concentrations of platelet AVP, factor VIII: C and von Willebrand factor.
    Nussey SS; Bevan DH; Ang VT; Jenkins JS
    Thromb Haemost; 1986 Feb; 55(1):34-6. PubMed ID: 3085262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet vasopressin receptor in patients with chronic renal failure.
    Inaba K; Umeda Y; Yamane Y; Urakami M; Nagata T; Inada M
    Nihon Jinzo Gakkai Shi; 1989 Oct; 31(10):1079-84. PubMed ID: 2533288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine diphosphate induced platelet aggregation and release reaction in heparinized platelet rich plasma and the influence of added citrate.
    Heptinstall S; Mulley GP
    Br J Haematol; 1977 Aug; 36(4):565-71. PubMed ID: 889719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of PGI2 and theophylline on the response of platelets subjected to shear stress.
    Hardwick RA; Hellums JD; Peterson DM; Moake JL; Olson JD
    Blood; 1981 Oct; 58(4):678-81. PubMed ID: 7023570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of matrix contact during gel filtration of human platelets in plasma.
    Lindon JN; Rodvien R; Waugh DF
    Thromb Haemost; 1976 Nov; 36(2):311-8. PubMed ID: 1036835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.